Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Approvals
A listing of EU centralized approvals of new active substances, including brand name, generic name, company, therapeutic category/indication, date of marketing authorization and product type (e.g., medicine, vaccine, biologic).
Co-primary endpoint was Axillary Sweating Daily Diary, a novel PRO instrument developed by Dermira with FDA input, assessed sweating severity and impact of sweating on a person’s daily activities; results complemented quantitative measure of sweat production in Phase III trials.
With at least 40 pending novel products, FDA seems poised to break its 2017 approval record of 46, and could even reach 60.
Takeda’s global blockbuster GI drug Entyvio has been approved in Japan, although its local sales prospects appear limited, while two novel cancer drugs from AstraZeneca and a world-first indication have also been cleared by the health ministry.
This is a monthly update listing recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.